0001140361-24-027025.txt : 20240521 0001140361-24-027025.hdr.sgml : 20240521 20240521160526 ACCESSION NUMBER: 0001140361-24-027025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240517 FILED AS OF DATE: 20240521 DATE AS OF CHANGE: 20240521 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Halpin Michael CENTRAL INDEX KEY: 0001778858 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 24969314 MAIL ADDRESS: STREET 1: C/O VERICEL CORPORATION STREET 2: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 4 1 form4.xml FORM 4 X0508 4 2024-05-17 0000887359 Vericel Corp VCEL 0001778858 Halpin Michael 64 SIDNEY STREET CAMBRIDGE MA 02139 true Chief Operating Officer false Common Stock 2024-05-17 4 M 0 2063 2.65 A 3152 D Common Stock 2024-05-17 4 M 0 3132 7.2 A 6284 D Stock Option (Right to Buy) 2.65 2024-05-17 4 M 0 2063 0 A 2027-04-10 Common Stock 2063 0 D Stock Option (Right to Buy) 7.2 2024-05-17 4 M 0 3132 0 A 2028-02-07 Common Stock 3132 0 D The Reporting Person has elected to exercise and hold these shares at this time. These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). These options, representing the right to purchase 135,000 shares, became exercisable on April 10, 2018, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. These options, representing the right to purchase 40,330 shares, became exercisable in equal quarterly installments, contingent upon continued service to the Company, with the first vesting date on May 7, 2018, which was one quarter after the date on which the option was granted. /s/ Sean Flynn, as Attorney-in-Fact for Michael Halpin 2024-05-21